DE602005015677D1 - 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen - Google Patents

2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen

Info

Publication number
DE602005015677D1
DE602005015677D1 DE602005015677T DE602005015677T DE602005015677D1 DE 602005015677 D1 DE602005015677 D1 DE 602005015677D1 DE 602005015677 T DE602005015677 T DE 602005015677T DE 602005015677 T DE602005015677 T DE 602005015677T DE 602005015677 D1 DE602005015677 D1 DE 602005015677D1
Authority
DE
Germany
Prior art keywords
arylpyramidines
amino
substituted
treatment
inflammatory diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005015677T
Other languages
German (de)
English (en)
Inventor
Paul E Fleming
Zhan Shi
Shaowu Chen
Jane F Schmidt
John C Reader
Neal D Hone
Jefrey P Ciavarri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34749013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005015677(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of DE602005015677D1 publication Critical patent/DE602005015677D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602005015677T 2004-01-08 2005-01-10 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen Expired - Lifetime DE602005015677D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53489804P 2004-01-08 2004-01-08
PCT/US2005/000663 WO2005066139A2 (en) 2004-01-08 2005-01-10 2-(amino-substituted)-4-aryl pyramidines and related compounds useful for treating inflammatory diseases

Publications (1)

Publication Number Publication Date
DE602005015677D1 true DE602005015677D1 (de) 2009-09-10

Family

ID=34749013

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005015677T Expired - Lifetime DE602005015677D1 (de) 2004-01-08 2005-01-10 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen

Country Status (18)

Country Link
US (2) US7732444B2 (enExample)
EP (2) EP2123647A1 (enExample)
JP (1) JP2007517895A (enExample)
AR (1) AR047185A1 (enExample)
AT (1) ATE437861T1 (enExample)
AU (1) AU2005204060A1 (enExample)
CA (1) CA2559888A1 (enExample)
CY (1) CY1109529T1 (enExample)
DE (1) DE602005015677D1 (enExample)
DK (1) DK1701944T3 (enExample)
ES (1) ES2330863T3 (enExample)
HR (1) HRP20090572T1 (enExample)
PL (1) PL1701944T3 (enExample)
PT (1) PT1701944E (enExample)
RS (1) RS51091B (enExample)
SI (1) SI1701944T1 (enExample)
TW (1) TW200533357A (enExample)
WO (1) WO2005066139A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
WO2005095386A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
JP2009521488A (ja) * 2005-12-21 2009-06-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｋｃ−シータのインヒビターとして有益なピリミジン誘導体
WO2007107543A1 (en) * 2006-03-22 2007-09-27 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
AU2008236679B2 (en) * 2007-04-03 2013-11-28 Fmc Corporation Substituted benzene fungicides
HUE024877T2 (en) * 2007-10-30 2016-02-29 Genentech Inc Antibody purification by cation exchange chromatography
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 ６員芳香環含有化合物
EP2169665B1 (en) 2008-09-25 2018-05-02 LG Electronics Inc. A method and an apparatus for processing a signal
EP2599494A1 (en) * 2010-01-11 2013-06-05 Healor Ltd. PKC inhibitors for the treatment of inflammatory disease or disorder
US20130109019A1 (en) * 2010-07-02 2013-05-02 Adrian E. Murillo Hapten conjugates for target detection
US9133187B2 (en) 2011-02-28 2015-09-15 Array Biopharma Inc. Serine/threonine kinase inhibitors
ES2552989T3 (es) 2011-08-04 2015-12-03 Array Biopharma, Inc. Compuestos de quinazolina como inhibidores de la cinasa de serina / treonina
PE20150666A1 (es) 2012-03-01 2015-05-06 Array Biopharma Inc Inhibidores de serina/treonina cinasa
SG11201406584TA (en) 2012-04-24 2014-11-27 Vertex Pharma Dna-pk inhibitors
CA2882750A1 (en) 2012-08-27 2014-03-06 Jim Blake Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
RS62649B1 (sr) 2013-03-12 2021-12-31 Vertex Pharma Inhibitori dnk-pk
CA2923765C (en) 2013-09-18 2021-06-29 University Of Canberra Stem cell modulation ii
KR102411227B1 (ko) 2013-10-17 2022-06-21 버텍스 파마슈티칼스 인코포레이티드 Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정
AU2015309686B2 (en) 2014-08-25 2020-05-14 Epiaxis Therapeutics Pty Ltd Compositions for modulating cancer stem cells and uses therefor
MX394860B (es) 2016-09-27 2025-03-24 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
WO2023104744A1 (en) 2021-12-06 2023-06-15 Helmholtz-Zentrum Dresden-Rossendorf E.V. 3-((3-([1,1'-biphenyl]-3-ylmethoxy)phenoxy)methyl)benzonitrile derivatives and the use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698697A (en) 1995-07-19 1997-12-16 Mitsubishi Chemical Corporation 2-cyanopiperazine and method of producing the same
JP2001526230A (ja) * 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CZ20012350A3 (cs) 1998-12-24 2001-09-12 Aventis Pharmaceuticals Products Inc. Substituované (aminoiminomethyl nebo aminomethyl) benzoheteroarylové sloučeniny
US6492516B1 (en) 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity
WO2001000214A1 (en) * 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
DE60039616D1 (de) 1999-08-13 2008-09-04 Vertex Pharma INHIBITOREN DER c-JUN N-TERMINALEN KINASE (JNK) UND ANDERE PROTEIN-KINASEN
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US6869956B2 (en) 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
EP1326865B1 (en) 2000-10-12 2009-05-06 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
MXPA03008888A (es) * 2001-03-29 2005-03-07 Vertex Pharma Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas.
DE60214701T2 (de) * 2001-04-13 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
GB0112803D0 (en) 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
MXPA04004166A (es) 2001-11-07 2004-07-08 Hoffmann La Roche Aminopirimidinas y piridinas.
TWI319387B (en) * 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
WO2003106451A1 (en) * 2002-06-14 2003-12-24 Altana Pharma Ag Substituted diaminopyrimidines
TW200510311A (en) 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
EP1590334B1 (en) 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
AU2004229392A1 (en) 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US7459460B2 (en) 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
WO2005095386A1 (en) * 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
MXPA06014247A (es) 2004-06-10 2007-03-12 Irm Llc Compuestos y composiciones como inhibidores de la proteina quinasa.
EP1809290A2 (en) * 2004-11-03 2007-07-25 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
AU2005316312B2 (en) 2004-12-17 2009-10-22 Amgen, Inc. Aminopyrimidine compounds and methods of use
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
DE102005034821A1 (de) * 2005-07-26 2007-02-08 Fleissner Gmbh Voluminöse Faserlaminate und ihre Herstellung
TWM293131U (en) * 2006-01-10 2006-07-01 Shuen Tai Prec Entpr Co Ltd Handheld power hammer

Also Published As

Publication number Publication date
ATE437861T1 (de) 2009-08-15
TW200533357A (en) 2005-10-16
PT1701944E (pt) 2009-11-03
CY1109529T1 (el) 2014-08-13
CA2559888A1 (en) 2005-07-21
SI1701944T1 (sl) 2010-03-31
US8268822B2 (en) 2012-09-18
EP2123647A1 (en) 2009-11-25
US7732444B2 (en) 2010-06-08
WO2005066139A3 (en) 2005-10-13
US20060040968A1 (en) 2006-02-23
ES2330863T3 (es) 2009-12-16
WO2005066139A2 (en) 2005-07-21
US20110071134A1 (en) 2011-03-24
EP1701944A2 (en) 2006-09-20
RS51091B (sr) 2010-10-31
AR047185A1 (es) 2006-01-11
AU2005204060A1 (en) 2005-07-21
EP1701944B1 (en) 2009-07-29
PL1701944T3 (pl) 2010-01-29
JP2007517895A (ja) 2007-07-05
DK1701944T3 (da) 2009-11-09
HRP20090572T1 (hr) 2010-01-31

Similar Documents

Publication Publication Date Title
ATE437861T1 (de) 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE415397T1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
ATE441417T1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
NL1026329A1 (nl) 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
NL1026327A1 (nl) 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
LTC2805723I2 (lt) Kladribino režimas, skirtas išsėtinei sklerozei gydyti
NL1026203A1 (nl) Verbindingen toepasbaar voor de behandeling van ziekten.
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
DE602005020263D1 (de) Für die behandlung von entzündlichen krankheiten nützliche beta-carboline
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
EP1965827A4 (en) TREATMENT OF CONDITIONS RELATED TO DEMYELINATION
DE602005015963D1 (de) Estergebundene makrolide, die sich für die behandlung von mikrobiellen infektionen eignen
NL1030418A1 (nl) Azabenzoxazolen voor de behandeling van CZS-stoornissen.
DE602005015434D1 (de) Mittel zur behandlung von psychoneurotischen krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition